<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100956</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00027272</org_study_id>
    <nct_id>NCT02100956</nct_id>
  </id_info>
  <brief_title>Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain</brief_title>
  <official_title>Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effect of oxytocin given into the spinal fluid
      on pain and areas and intensity of hyperalgesia and allodynia in patients with chronic
      neuropathic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: The investigators anticipate that oxytocin will be effective after spinal
      injection in humans to acutely relieve chronic neuropathic pain.

      Objectives: Determine the effect of intrathecal oxytocin on pain and areas and intensity of
      hyperalgesia and allodynia in patients with chronic neuropathic pain.

      Interventions: A computer generated randomization will be used to determine the group for
      each subject. Subjects will be randomized to receive an intrathecal injection of saline
      (placebo) or oxytocin.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>60 minutes post injection</time_frame>
    <description>Pain will be measured by visual analog scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxytocin 100 micrograms administered intrathecally (IT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>preservative free normal saline: 3 milliliters administered intrathecally (IT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin 100 micrograms</intervention_name>
    <description>oxytocin 100 micrograms administered intrathecally (IT)</description>
    <arm_group_label>oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline (preservative free)</intervention_name>
    <description>Normal Saline (preservative free) administered intrathecally (IT)</description>
    <arm_group_label>normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight &lt; or equal to 240 pounds

          -  Neuropathic pain for &gt; 6 months: with primary pain area below the umbilicus

        Exclusion Criteria:

          -  Hypersensitivity, allergy, or significant reaction to any ingredient of the study drug
             or lidocaine

          -  Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the
             Principal Investigator, would place the subject at increased risk (active gynecologic
             disease in which increased tone would be detrimental e.g., uterine fibroids with
             ongoing bleeding), compromise the subject's compliance with study procedures, or
             compromise the quality of the data

          -  Pregnancy

          -  spinal cord stimulators, chronic intrathecal drug therapy, or oral opioid treatment
             for &gt; 3 months at a current dose of &gt; 100 milligram (mg) morphine per day or
             equivalent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C. Eisenach, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>March 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic pain</keyword>
  <keyword>neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

